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Abstract 
Background: South Asians have a high risk to develop type 2 diabetes, which may be related to substantial ectopic 
fat deposition. Since glucagon‑like peptide‑1 analogues can reduce ectopic fat accumulation, the aim of the present 
study was to assess the effect of treatment with liraglutide for 26 weeks on ectopic fat deposition and HbA1c in South 
Asian patients with type 2 diabetes.
Methods: In a placebo‑controlled trial, 47 South Asian patients with type 2 diabetes were randomly assigned to 
treatment with liraglutide (1.8 mg/day) or placebo added to standard care. At baseline and after 26 weeks of treat‑
ment we assessed abdominal subcutaneous, visceral, epicardial and paracardial adipose tissue volume using MRI. Fur‑
thermore, myocardial and hepatic triglyceride content were examined with proton magnetic resonance spectroscopy.
Results: In the intention‑to‑treat analysis, liraglutide decreased body weight compared to placebo (− 3.9 ± 3.6 kg vs 
− 0.6 ± 2.2 kg; mean change from baseline (liraglutide vs placebo): − 3.5 kg; 95% CI [− 5.3, − 1.8]) without significant 
effects on the different adipose tissue compartments. HbA1c was decreased in both groups without between group 
differences. In the per‑protocol analysis, liraglutide did decrease visceral adipose tissue volume compared to placebo 
(− 23 ± 27 cm2 vs − 2 ± 17 cm2; mean change from baseline (liraglutide vs placebo): − 17 cm2; 95% CI [− 32, − 3]). 
Furthermore, HbA1c was decreased by liraglutide compared to placebo (− 1.0 ± 0.8% (− 10.5 ± 9.1 mmol/mol)) vs 
(− 0.6 ± 0.8% (− 6.1 ± 8.8 mmol/mol)), with a between group difference (mean change from baseline (liraglutide vs 
placebo): − 0.6% (− 6.5 mmol/mol); 95% CI [− 1.1, − 0.1 (− 11.5, − 1.5)]). Interestingly, the decrease of visceral adipose 
tissue volume was associated with the reduction of HbA1c (β: 0.165 mmol/mol (0.015%) per 1 cm2 decrease of vis‑
ceral adipose tissue volume; 95% CI [0.062, 0.267 (0.006, 0.024%)]).
Conclusions: While the intention‑to‑treat analysis did not show effects of liraglutide on ectopic fat and HbA1c, 
per‑protocol analysis showed that liraglutide decreases visceral adipose tissue volume, which was associated with 
improved glycaemic control in South Asians.
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Background
South Asians are at high risk to develop type 2 diabetes 
in comparison with other populations, with an estimated 
prevalence of type 2 diabetes of 8.5% in the adult popula-
tion [1]. Furthermore, South Asians tend to develop type 
2 diabetes at a young age and at a low BMI [2]. Notably, 
at a BMI of 21 kg/m2 South Asians show similar distribu-
tions of variables for glucose metabolism as white Cau-
casians at a BMI of 30  kg/m2 [3]. The underlying cause 
of the increased risk to develop type 2 diabetes remains 
largely unknown, but an increased amount of ectopic 
fat is likely to play a role [4]. It is well known that cen-
tral obesity, but also increased accumulation of ectopic 
fat in liver [5] and muscle [6] play an important role in 
development of insulin resistance and type 2 diabetes [7]. 
Interestingly, several studies have shown that, compared 
to Europids with a similar BMI, South Asians have more 
visceral adipose tissue [8, 9] and a higher intrahepatic 
triglyceride content [10, 11]. Ectopic fat accumulation 
increases insulin resistance and metabolic risk [12, 13], 
but may also contribute to remodelling of the heart and 
to diastolic dysfunction [14]. Therefore, interventions 
focussed on reducing ectopic fat accumulation could be 
an effective approach to reduce insulin resistance and 
improve glycaemic control in this population.
Glucagon-like peptide-1 (GLP-1) analogues are pre-
scribed to patients with type 2 diabetes to improve gly-
caemic control and induce weight loss [15, 16]. The 
reduction in body weight is primarily the result of a 
reduction in fat mass, but this reduction does not seem 
to occur homogeneously in different adipose tissue 
depots in the body [17, 18]. Recently, it has been shown 
that liraglutide, a GLP-1 analogue, reduces hepatic stea-
tosis in patients with non-alcoholic steatohepatitis [19]. 
Furthermore, previous studies investigating the effect 
of GLP-1 analogues on different fat depots, have shown 
that while both subcutaneous and visceral adipose tissue 
are reduced, the decrease of visceral adipose tissue [17, 
20], and epicardial fat [18, 21] is even more pronounced. 
However, in another study mainly subcutaneous adipose 
tissue was reduced after treatment, while visceral adi-
pose tissue was not affected [22]. Several studies have 
recently suggested that subcutaneous adipose tissue does 
not increase the risk to develop diabetes and might even 
possess protective properties [23, 24]. Visceral adipose 
tissue, however, is causally linked to insulin resistance 
[25]. Apparently, conflicting data have been reported 
with respect to the effect of GLP-1 analogues on the 
various adipose depots in the general population. Since 
it is unclear to what extent different adipose tissue com-
partments are affected by weight loss induced by treat-
ment with GLP-1 analogues, it is important to further 
investigate the effects of treatment with GLP-1 analogues 
on the different fat depots, especially since reduction 
of ectopic adipose tissue would be more beneficial than 
reduction of subcutaneous adipose tissue.
Since South Asians have a specific body fat distribu-
tion, with high amounts of visceral adipose tissue [8, 9], 
effects of a GLP-1 analogue on ectopic fat depots, and 
subsequently effects on glycaemic control, could be pro-
nounced especially in this population. Therefore, the aim 
of the present study was to assess the effect of treatment 
with liraglutide for 26  weeks on ectopic fat deposition 
and HbA1c in South Asian patients with type 2 diabetes.
Methods
Study overview and study population
This study is a 26-week, prospective, randomised, 
double-blind, clinical trial. Patients from South Asian 
descent, i.e. individuals with two South Asian parents, 
with type 2 diabetes were recruited via advertisements 
and from the outpatient clinics of the Leiden Univer-
sity Medical Center (LUMC, Leiden, The Netherlands), 
general practitioners, and local hospitals. A screening 
visit was performed prior to inclusion to assess eligibil-
ity for participation. We included subjects with BMI 
≥ 23  kg/m2, aged 18–74  years, with an HbA1c ≥ 6.5% 
and ≤ 11.0% (≥ 47.5 and ≤ 96.4  mmol/mol). Concomi-
tant treatment with metformin, sulfonylurea deriva-
tives and insulin was optional, although the dosage of 
all glucose-lowering medication needed to be stable for 
at least 3 months prior to participation. Main exclusion 
criteria were use of other glucose-lowering therapy than 
mentioned above or presence of renal disease, congestive 
heart failure New York Heart Association (NYHA) classi-
fication III–IV, uncontrolled hypertension (systolic blood 
pressure > 180  mmHg and/or diastolic blood pressure 
> 110  mmHg) or an acute coronary or cerebrovascular 
accident within 30 days prior to study inclusion. Further-
more, patients with any contra-indication for contrast-
enhanced MRI were excluded. The trial was conducted in 
accordance with the principles of the revised Declaration 
of Helsinki. Written informed consent was obtained from 
all subjects before inclusion. The trial was approved by 
the local ethics committee and conducted at the LUMC, 
and was registered at clinicaltrials.gov (NCT01761318).
Keywords: South Asian, Diabetes mellitus type 2, Ectopic fat, GLP‑1 analogue, Liraglutide, Randomised clinical trial, 
Magnetic resonance imaging, Magnetic resonance spectroscopy
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Study design
At baseline, participants were randomised to receive 
treatment with liraglutide  (Victoza®) or placebo (both 
provided by Novo Nordisk A/S, Bagsvaerd, Denmark) 
by block randomisation with block size of 4 and strati-
fication 1:1 for sex and insulin use. During the study, all 
participants, study investigators and outcome assessors 
were blinded to treatment allocation. The starting dose 
of the study medication was 0.6 mg per day, which was 
titrated in 2  weeks to a maximum dose of 1.8  mg per 
day, if tolerated. If necessary in case of adverse events, 
the dose was reduced. During trial participation, a 
weekly telephone call was scheduled to discuss blood 
glucose management and adverse events, and at week 
4 and week 12 participants visited the study center for 
routine blood tests and clinical measurements. In addi-
tion to study medication, participants received treat-
ment according to current clinical guidelines to achieve 
optimal glycaemic control and regulation of blood pres-
sure and cholesterol levels.
Data collection
After inclusion, participants visited the study center at 
baseline and after 26  weeks of treatment, after ≥ 6  h of 
fasting, for medical history assessment, standard physi-
cal examination, collection of venous blood samples and 
MRI. All blood samples were centrifuged and stored at 
− 80  °C until analysis. Plasma total cholesterol, HDL-
cholesterol and triglyceride concentrations were meas-
ured on a Modular P800 analyser (Roche Diagnostics, 
Mannheim, Germany). LDL-cholesterol was calculated 
according to the Friedewald formula [26]. HbA1c was 
assessed with ion-exchange high-performance liquid 
chromatography (HPLC; Tosoh G8, Sysmex Nederland 
B.V., Etten-Leur, the Netherlands). Body composition and 
lean body mass was assessed using bioelectrical imped-
ance analysis (BIA; Bodystat 1500, Bodystart Ltd., Doug-
las, UK).
MRI for adipose tissue volume
A 3.0 Tesla MRI scanner (Ingenia, Philips Healthcare, 
Best, the Netherlands) was used, with a dStream Torso 
anterior coil and a FlexCoverage posterior coil in the 
table top (in total up to 32 coil elements for signal recep-
tion). To assess visceral and abdominal subcutaneous 
adipose tissue volumes, 2-point Dixon water-fat sepa-
rated transverse images were obtained of the abdomen 
during one breath-hold, with the following parameters: 
repetition time (TR) 3.5 ms, first/second echo time (TE1/
TE2) 1.19/2.3 ms, flip angle (FA) 10°, field of view (FOV) 
500 × 365 mm2, acquired voxel size 1.60 × 1.70 mm2, slice 
thickness 4 mm, slice gap − 2 mm, and number of slices 
140.
For quantification of epicardial and paracardial fat, 
ECG-triggered fat-selective images, using a multi-shot 
turbo spin-echo sequence with spectral pre-saturation 
with inversion recovery (SPIR) for water suppression, 
were acquired in 4-chamber view orientation at end-
diastole, during one breath-hold, with imaging param-
eters: TR/TE 1000/11  ms, FA 90°, FOV 280 × 223  mm2, 
acquired voxel size 1.09 × 1.12  mm2, and slice thickness 
4 mm.
MR images were analysed in MASS Research Soft-
ware V2018-EXP (Leiden University Medical Center, the 
Netherlands). For assessment of visceral and abdominal 
subcutaneous adipose tissue volume, three transverse 
slices were reformatted, at the level of the fourth and 
fifth lumbar vertebrae, with slice thickness of 10  mm 
and slice gap of 12 mm. In each slice, the outer borders 
of visceral and subcutaneous adipose tissue were manu-
ally outlined, and the areas were automatically calculated 
based on pixel intensity thresholding. Subsequently, vis-
ceral and abdominal subcutaneous adipose tissue volume 
were quantified as the mean area in squared centimeters 
of all three slices. Similarly, epicardial and paracardial fat 
(between outer wall of the myocardium and visceral peri-
cardium and between visceral and parietal pericardium, 
respectively) were assessed. Epicardial and paracardial 
fat were measured in 4 chamber view orientation, in the 
region surrounding the left and right ventricles, below 
the level of the atrioventricular valves.
Proton magnetic resonance spectroscopy for myocardial 
and hepatic triglyceride content
Myocardial and hepatic triglyceride content were exam-
ined with proton magnetic resonance spectroscopy (1H-
MRS) [27]. Spectra were acquired using single voxel point 
resolved spectroscopy (PRESS), with first order volume 
B0 pencil beam shimming, respiratory navigator (trig-
ger and track), and multiply optimized insensitive sup-
pression train (MOIST) suppression (bandwidth 190 Hz) 
for the water-suppressed acquisitions. Parameters were 
as follows: TR 3.5 or 9  s (water-suppressed and non-
water-suppressed acquisition, respectively), TE 35  ms, 
bandwidth 1500 Hz and acquired samples 2048 (spectral 
resolution 0.73  Hz/sample). Cardiac 1H-MRS addition-
ally used ECG-triggering (R-top trigger delay 200  ms) 
and acquired in the midventricular septum (voxel size 
40 × 15 × 25 mm3, shim volume 50 × 25 × 35 mm3, num-
ber of signal averages (NSA) of water-suppressed and 
non-water-suppressed acquisition 64 and 6, respec-
tively). A high permittivity pad was placed on the thorax 
at the location of the heart to improve signal-to-noise 
ratio [28]. Hepatic 1H-MRS was obtained in the liver 
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parenchyma, avoiding the inclusion of blood vessels or 
subcutaneous fat (voxel size 20 × 20 × 20 mm3, shim vol-
ume 35 × 35 × 35  mm3, NSA of water-suppressed and 
non-water-suppressed acquisition 32 and 8, respectively). 
The voxels were planned at the same location for the 
baseline and follow-up measurements.
The spectral raw data were processed using an in-house 
developed script (MATLAB R2015a (MathWorks, Mas-
sachusetts, United States). The raw data were phase-, 
frequency- and eddy current-corrected, if required. Indi-
vidual signal averages were analysed and signal averages 
exceeding the 95% confidence interval were considered 
outliers and were excluded. Reconstructed data were 
further analysed in the Java-based Magnetic Resonance 
User Interface (jMRUI v5.0; MRUI Consortium). For the 
water-suppressed signals, the Hankel–Lanczos filter was 
applied to remove residual water. The spectra were fitted 
using the AMARES algorithm, with the assumption of 
Gaussian line shapes. Prior knowledge for the fit included 
the following starting values: triglyceride-methyl  (CH3) 
0.9 ppm, triglyceride-methylene  (CH2) 1.3 ppm, COO–
CH2 2.05 ppm, creatine 3.05  ppm, trimethylamines 
(TMA) 3.25 ppm, with soft constraints for the linewidth 
of the fit of each signal. The first-order phase was fixed to 
zero. Myocardial and hepatic lipid-to-water ratios were 
quantified as the signal of triglyceride methylene divided 
by the unsuppressed water signal, multiplied by 100% 
[29].
Statistical analyses
The main outcome measure of this study was the effect 
of liraglutide on cardiac function and sample size calcu-
lation was based on this outcome measure as described 
previously [30]. In this manuscript, we report on second-
ary outcome measures. Data are shown as mean ± SD, 
or as median (interquartile range) when not normally 
distributed. Within-group changes were assessed using 
paired t-tests. We performed an ANCOVA to assess 
between-group differences with treatment included as 
fixed effect and the baseline value as a covariate. The 
intention-to-treat analysis included data of all partici-
pants who were randomised and started study medica-
tion. The per-protocol analysis included only participants 
who adhered to the assigned medication, i.e. used ≥ 80% 
of prescribed study medication. A P-value < 0.05 was con-
sidered statistically significant. Statistical analyses were 
performed using SPSS version 23.0 for Windows (IBM 
Corporation, Chicago, IL).
Results
Population characteristics
As shown in the trial flow diagram in Fig. 1, 51 patients 
were included after screening, of whom 4 were excluded 
before randomisation. Between July 2015 and December 
2016, 22 patients were randomised to receive liraglutide 
and 25 to receive placebo. All randomised patients fin-
ished the study and were included in the intention-to-
treat analysis. During the study, 19 participants (86.4%) 
of the liraglutide group and 24 participants (96.0%) of 
the placebo group used the standard dose of 1.8 mg/day, 
while in the rest of the participants the maximally toler-
ated dose was 1.2 mg/day. In the liraglutide group, par-
ticipants used on average 95.4 ± 8.1% of the prescribed 
cumulative dose, and in the placebo group the partici-
pants used 98.7 ± 5.2%. One participant of the liraglutide 
group used < 80% of the prescribed cumulative dose, and 
of two participants (one allocated to receive placebo and 
one to receive liraglutide) adherence could not be cal-
culated, due to missing (empty) medication pens. These 
participants were included in the intention-to-treat 
analysis but not in the per-protocol analysis. One serious 
adverse event (admission for symptoms of acute coronary 
syndrome) occurred in the placebo group. In the liraglu-
tide group compared to the placebo group, more partici-
pants reported nausea (73 vs 40%) and vomiting (27 vs 
8%) at least once during study participation. As shown 
in Table 1, baseline characteristics of the participants in 
both treatment groups were balanced. Individuals were 
55 ± 11 years old in the liraglutide group, vs 55 ± 9 years 
in the placebo group, with a body weight of 81.9 ± 11.0 vs 
77.8 ± 12.4 kg and BMI of 30.4 ± 3.8 vs 28.6 ± 4.0 kg/m2, 
respectively.
Effects of liraglutide on body weight and ectopic fat 
in the intention‑to‑treat analysis
Results of the intention-to-treat analysis are shown 
in Table  2. Treatment with liraglutide for 26  weeks 
decreased body weight, while body weight in participants 
treated with placebo was not affected (− 3.9 ± 3.6  kg vs 
− 0.6 ± 2.2  kg; mean change from baseline (liraglutide 
vs placebo): − 3.5 kg; 95% CI [− 5.3, − 1.8]). Part of this 
weight loss was explained by a decrease in lean body 
mass that occurred in the liraglutide group but not in 
the placebo group (− 2.3 ± 2.3  kg vs 0.4 ± 2.9  kg; mean 
change from baseline (liraglutide vs placebo): − 2.7  kg; 
95% CI [− 4.3, − 1.1]). Notably, waist circumference was 
decreased by liraglutide, while hip circumference was 
unaffected. Furthermore, although liraglutide decreased 
body weight, no effect was present on the investigated 
separate adipose tissue compartments, with the excep-
tion of a tendency to a decreased visceral adipose tissue 
volume in the liraglutide group compared to the placebo 
group (− 20 ± 29 cm2 vs − 2 ± 17 cm2; mean change from 
baseline (liraglutide vs placebo): − 13 cm2; 95% CI [− 27, 
1]).
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Fig. 1 Trial flow diagram
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Effects of liraglutide on HbA1c and lipid levels 
in the intention‑to‑treat analysis
In the intention-to-treat analysis HbA1c was 
decreased in the liraglutide group (− 8.5 ± 11.2  mmol/
mol; − 0.8 ± 1.0%), but also in the placebo group 
(− 6.8 ± 9.3  mmol/mol; − 0.6 ± 0.8%), without between 
group differences (mean change from baseline (lira-
glutide vs placebo): − 4.0  mmol/mol (− 0.4%); 95% CI 
[− 9.7, 1.6 (− 0.9, 0.1%)]. To improve glycaemic control 
metformin was started for 1 participant and sulfonylurea 
derivatives were started in 3 participants of the placebo 
group according to clinical guidelines. The mean insulin 
dose was not significantly changed compared to baseline 
in the liraglutide and the placebo group (− 11 ± 34 units/
day vs 1 ± 23 units/day; mean change from baseline (lira-
glutide vs placebo): − 12 units/day; 95% CI [− 31, 8]). 
Furthermore, while glycaemic control was improved in 
both groups, total cholesterol, HDL-cholesterol, LDL-
cholesterol and triglyceride were not affected.
Effects of liraglutide on ectopic fat and HbA1c 
in the per‑protocol analysis
Results of the per protocol analysis are shown in Table 3. 
In this analysis, 3 patients who used < 80% of the pre-
scribed cumulative dose were excluded from analysis, 
of whom 2 were randomised to receive liraglutide and 1 
to receive placebo. As in the intention-to-treat analysis, 
treatment with liraglutide decreased body weight and lean 
body mass. Furthermore, as shown in Fig. 2, visceral adi-
pose tissue volume was decreased by liraglutide, but not 
by placebo (− 23 ± 27 cm2 vs − 2 ± 17 cm2; mean change 
from baseline (liraglutide vs placebo): − 17 cm2; 95% CI 
[− 32, − 3]). Other adipose tissue compartments were 
not affected by treatment with liraglutide. HbA1c was 
decreased in the liraglutide group (− 10.5 ± 9.1  mmol/
mol; − 1.0 ± 0.8%) to a greater extent than in the pla-
cebo group (− 6.1 ± 8.8  mmol/mol; − 0.6 ± 0.8%), with 
a between group difference (mean change from baseline 
(liraglutide vs placebo) of: − 6.5 mmol/mol (− 0.6%); 95% 
CI [− 11.5, − 1.5 (− 1.1, − 0.1%)]. Interestingly, an asso-
ciation was present between the decrease of subcutane-
ous adipose tissue volume and HbA1c after treatment (β: 
0.075 mmol/mol (0.007%) per 1 cm2 decrease of subcuta-
neous adipose tissue volume; 95% CI [0.004, 0.146 (0.000, 
0.013%)]) (Fig.  3a). A similar but stronger association 
was present between the decrease of visceral adipose tis-
sue volume and the reduction of HbA1c after treatment 
(β: 0.165 mmol/mol (0.015%) per 1 cm2 decrease of vis-
ceral adipose tissue volume; 95% CI [0.062, 0.267 (0.006, 
0.024%)]) (Fig. 3b). No association was present between 
other adipose tissue compartments and HbA1c.
Discussion
In this double-blind, randomised placebo-controlled trial 
in South Asian patients with type 2 diabetes, we observed 
that liraglutide decreased body weight. Although this 
was not accompanied by effects on specific adipose tis-
sue compartments in the intention-to-treat analysis, lira-
glutide did decrease visceral adipose tissue volume and 
HbA1c compared to placebo in the per-protocol analy-
sis. In fact, the reduction in visceral adipose tissue was 
Table 1 Baseline characteristics of study participants
Results are presented as n (%) or mean ± SD. n = 47. Missing data in liraglutide 
group: n = 1 for epicardial adipose tissue volume and paracardial adipose tissue 
volume. Missing data in placebo group: n = 1 for lean body mass (kg and %), 
epicardial adipose tissue volume and myocardial triglyceride content
AT adipose tissue, TGC triglyceride content
Characteristic Liraglutide (n = 22) Placebo (n = 25)
Demographics
 Age (year) 55 ± 11 55 ± 9
Sex (no. (%))
 Male 8 (36%) 11 (44%)
 Female 14 (64%) 14 (56%)
Diabetes duration (years) 19 ± 10 17 ± 10
Concomitant drug use
 Metformin (no. (%)) 22 (100%) 23 (92%)
 Metformin dose (g/day) 1.8 ± 0.7 1.7 ± 0.6
 Sulfonylurea (no. (%)) 3 (14%) 5 (20%)
 Insulin (no. (%)) 17 (77%) 19 (76%)
 Insulin dose (units/day) 77 ± 34 67 ± 30
 Lipid‑lowering drugs (statin 
and/or other), no. (%)
17 (77%) 20 (80%)
Clinical parameters
 Body weight (kg) 81.9 ± 11.0 77.8 ± 12.4
 BMI (kg/m2) 30.4 ± 3.8 28.6 ± 4.0
 Waist circumference (cm) 104 ± 8 98 ± 10
 Hip circumference (cm) 104 ± 7 104 ± 9
 Waist‑hip ratio 1.00 ± 0.07 0.95 ± 0.09
 Lean body mass (kg) 51.6 ± 10.6 48.9 ± 11.2
 Lean body mass (%) 62.8 ± 8.4 63.1 ± 9.8
Metabolic factors
 HbA1c (mmol/mol) 65 ± 10 70 ± 12
 HbA1c (%) 8.1 ± 0.9 8.6 ± 1.1
 Total cholesterol (mmol/L) 3.95 ± 0.65 4.46 ± 1.10
 HDL‑cholesterol (mmol/L) 1.24 ± 0.33 1.21 ± 0.30
 LDL‑cholesterol (mmol/L) 2.00 ± 0.65 2.21 ± 0.97
 Triglycerides (mmol/L) 1.55 ± 0.86 2.08 ± 1.80
Adipose tissue compartments
 Subcutaneous AT  (cm2) 315 ± 97 326 ± 141
 Visceral AT  (cm2) 187 ± 57 149 ± 49
 Epicardial AT  (cm2) 10 ± 3 9 ± 3
 Paracardial AT  (cm2) 12 ± 4 9 ± 4
 Hepatic TGC (%) 6.9 ± 6.3 11.8 ± 10.9
 Myocardial TGC (%) 0.9 ± 0.4 1.0 ± 0.6
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associated with an improved HbA1c. These data imply 
that GLP-1 analogues such as liraglutide are an effective 
treatment option for South Asian patients with type 2 
diabetes that might improve glycaemic control by reduc-
ing visceral adipose tissue volume.
We are the first to investigate the effects of liraglutide 
on ectopic fat deposition in a group of South Asians par-
ticipants. Although the intention-to-treat analysis did 
not reveal a significant effect of liraglutide on ectopic fat, 
a trend towards a reduction of visceral adipose tissue vol-
ume was observed. This was likely caused by non-adher-
ence of a few participants to the study protocol, as the 
per-protocol analysis did show that liraglutide decreased 
visceral adipose tissue. These data are in accordance with 
results published by Jendle et  al. [17], who reported a 
dose-dependent reduction of visceral adipose tissue and 
a relatively small reduction of subcutaneous adipose tis-
sue after treatment with 0.6, 1.2 or 1.8 mg liraglutide per 
day for 26 or 52  weeks in a mixed population. In line, 
Ishii et  al. [20] reported that by treatment of Japanese 
individuals with liraglutide (0.9  mg/day for 26  weeks) 
reduced visceral adipose tissue volume without effects on 
subcutaneous adipose tissue. On the other hand, Suzuki 
et  al. [22] reported that treatment of Japanese individu-
als with liraglutide (0.9  mg/day for 26  weeks) reduced 
subcutaneous adipose tissue volume without effects on 
visceral adipose tissue volume. Furthermore, in a study 
performed by Morano et  al. [18], treatment of patients 
with type 2 diabetes with liraglutide (1.2  mg/day for 
12 weeks) or exenatide, another GLP-1 analogue, resulted 
in a reduction of epicardial fat volume as assessed by 
ultrasonography. Iacobellis et  al. [21] reported a simi-
lar reduction in epicardial fat volume after treatment 
with liraglutide (up to 1.8  mg/day for 3 and 6  months) 
and it was recently reported that epicardial adipose tis-
sue expresses the GLP-1 receptor [31]. This is of clinical 
importance, since it was recently shown that inflamma-
tory activity of epicardial adipose tissue volume might 
induce myocardial remodelling and dysfunction [32]. 
In the current study, a reduction of either epicardial or 
Table 2 Clinical parameters, metabolic factors and  adipose tissue compartment changes from  baseline after  26  weeks 
of treatment in the intention-to-treat analysis
Results are presented as n (%) or mean ± SD. n = 47. Missing data in the liraglutide group: n = 3 for epicardial adipose tissue volume and paracardial adipose tissue 
volume, n = 1 for myocardial TGC. Missing data in placebo group: n = 1 for lean body mass (kg and %), n = 3 for epicardial adipose tissue volume, n = 2 for paracardial 
adipose tissue volume, and n = 1 for myocardial TGC 
AT adipose tissue, TGC triglyceride content
Characteristic Mean ± SD change from baseline to 26 weeks Mean [95% CI] changes 
from baseline (liraglutide vs 
placebo)
P value
Liraglutide (n = 22) Placebo (n = 25)
Clinical parameters
 Body weight (kg) − 3.9 ± 3.6 − 0.6 ± 2.2 − 3.5 [− 5.3, − 1.8] < 0.001
 BMI (kg/m2) − 1.5 ± 1.4 − 0.2 ± 0.8 − 1.4 [− 2.0, − 0.7] < 0.001
 Waist circumference (cm) − 5 ± 4 0 ± 4 − 5 [− 8, − 2] < 0.001
 Hip circumference (cm) − 4 ± 5 − 2 ± 3 − 2 [− 5, 0] 0.067
 Waist‑hip ratio − 0.01 ± 0.04 0.02 ± 0.05 − 0.01 [− 0.04, 0.01] 0.312
 Lean body mass (kg) − 2.3 ± 2.3 0.4 ± 2.9 − 2.7 [− 4.3, − 1.1] 0.001
 Lean body mass (%) 0.2 ± 1.7 0.8 ± 2.7 − 0.6 [− 1.9, 0.8] 0.403
Metabolic factors
 HbA1c (mmol/mol) − 8.5 ± 11.2 − 6.8 ± 9.3 − 4.0 [− 9.7, 1.6] 0.156
 HbA1c (%) − 0.8 ± 1.0 − 0.6 ± 0.8 − 0.4 [− 0.9, 0.1] 0.156
 Total cholesterol (mmol/L) 0.24 ± 1.09 − 0.42 ± 0.82 0.52 [− 0.05, 1.09] 0.073
 HDL‑cholesterol (mmol/L) − 0.04 ± 0.12 − 0.05 ± 0.12 0.02 [− 0.05, 0.09] 0.657
 LDL‑cholesterol (mmol/L) 0.15 ± 0.74 − 0.14 ± 0.74 0.22 [− 0.20, 0.63] 0.296
 Triglycerides (mmol/L) 0.28 ± 1.25 − 0.38 ± 1.30 0.40 [− 0.24, 1.04] 0.214
Adipose tissue compartments
 Subcutaneous AT  (cm2) − 24 ± 37 − 10 ± 37 − 15 [− 37, 6] 0.158
 Visceral AT  (cm2) − 20 ± 29 − 2 ± 17 − 13 [− 27, 1] 0.074
 Epicardial AT  (cm2) 0 ± 2 1 ± 1 − 1 [− 2, 0] 0.232
 Paracardial AT  (cm2) − 1 ± 3 0 ± 3 − 1 [− 2, 1] 0.494
 Hepatic TGC (%) − 1.2 ± 4.1 − 3.3 ± 5.4 0.4 [− 1.9, 2.8] 0.704
 Myocardial TGC (%) 0.1 ± 0.5 − 0.1 ± 0.6 0.2 [− 0.1, 0.5] 0.157
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paracardial adipose tissue volume was not observed after 
treatment with liraglutide in South Asians as assessed by 
MRI, which is considered the gold standard for assess-
ment of body fat, including epicardial fat [33]. The rea-
son for the discrepancy with previously published results 
is unclear but may reflect an ethnic-specific response to 
liraglutide. There are indications for this from a study 
comparing the effect of very low calorie diet in middle-
aged South Asians to Western Europeans. While the very 
low calorie diet equally reduced body weight in both 
groups, the diet reduced pericardial adipose tissue, which 
includes epicardial adipose tissue, in the Western Europe-
ans only [34]. Similarly, we did not reproduce the results 
of Armstrong et  al. [19], who reported a histologically 
assessed reduction of hepatic steatosis in patients with 
steatohepatitis after treatment with liraglutide (1.8  mg/
day for 48 weeks) and of Dutour et al. [35] who reported 
reduction of hepatic steatosis in obese subjects with type 
2 diabetes after treatment with exenatide (20 µg/day for 
26  weeks). However, the patients in those studies had 
considerably higher severity of steatosis comparted to 
our participants who had a more modest hepatic triglyc-
eride content. These data may indicate that the potency 
of liraglutide to reduce hepatic steatosis is dependent on 
hepatic triglyceride content, although an ethnic-specific 
response to liraglutide cannot be ruled out.
In our trial, in the intention-to-treat analysis, treatment 
with both liraglutide and placebo resulted in reduction of 
HbA1c. Importantly, both groups were treated accord-
ing to current clinical guidelines. Therefore, if neces-
sary, the dose of glucose lowering medication, including 
insulin, was increased or new medication was started 
in both groups, which can thus explain the effect of 
placebo on HbA1c. These results are in line with previ-
ously published studies reporting no significant superior-
ity of GLP-analogues over standard treatment [36–38]. 
Table 3 Clinical parameters, metabolic factors and  adipose tissue compartment changes from  baseline after  26  weeks 
of treatment in the per-protocol analysis
Results are presented as n (%) or mean ± SD. n = 44. Missing data in the liraglutide group: n = 3 for epicardial adipose tissue volume and paracardial adipose tissue 
volume. Missing data in placebo group: n = 1 for lean body mass (kg and %), n = 3 for epicardial adipose tissue volume, n = 2 for paracardial adipose tissue volume, 
and n = 1 for myocardial triglyceride content
AT adipose tissue, TGC triglyceride content
Characteristic Mean ± SD change from baseline to 26 weeks Mean [95% CI] changes 
from baseline (liraglutide vs 
placebo)
P value
Liraglutide (n = 20) Placebo (n = 24)
Clinical parameters
 Body weight (kg) − 4.3 ± 3.4 − 0.6 ± 2.2 − 4.0 [− 5.8, − 2.3] < 0.001
 BMI (kg/m2) − 1.6 ± 1.4 − 0.2 ± 0.9 − 1.5 [− 2.2, − 0.8] < 0.001
 Waist circumference (cm) − 5 ± 4 0 ± 4 − 5 [− 8, − 2] 0.001
 Hip circumference (cm) − 4 ± 5 − 2 ± 3 − 2 [− 5, 0] 0.068
 Waist‑hip ratio − 0.01 ± 0.04 0.02 ± 0.05 − 0.01 [− 0.04, 0.02] 0.394
 Lean body mass (kg) − 2.4 ± 2.4 0.4 ± 3.0 − 2.8 [− 4.5, − 1.1] 0.002
 Lean body mass (%) 0.4 ± 1.6 0.8 ± 2.7 − 0.4 [− 1.8, 1.0] 0.605
Metabolic factors
 HbA1c (mmol/mol) − 10.5 ± 9.1 − 6.1 ± 8.8 − 6.5 [− 11.5, − 1.5] 0.011
 HbA1c (%) − 1.0 ± 0.8 − 0.6 ± 0.8 − 0.6 [− 1.1, − 0.1] 0.011
 Total cholesterol (mmol/L) 0.06 ± 0.98 − 0.37 ± 0.78 0.28 [− 0.26, 0.81] 0.305
 HDL‑cholesterol (mmol/L) − 0.04 ± 0.12 − 0.06 ± 0.11 0.02 [− 0.05, 0.10] 0.510
 LDL‑cholesterol (mmol/L) 0.04 ± 0.66 − 0.07 ± 0.68 0.08 [− 0.32, 0.48] 0.689
 Triglycerides (mmol/L) 0.12 ± 1.13 − 0.38 ± 1.32 0.13 [− 0.47, 0.74] 0.663
Adipose tissue compartments
 Subcutaneous AT  (cm2) − 26 ± 38 − 11 ± 37 − 15 [− 38, 7] 0.182
 Visceral AT  (cm2) − 23 ± 27 − 2 ± 17 − 17 [− 32, − 3] 0.020
 Epicardial AT  (cm2) 0 ± 2 1 ± 1 − 1 [− 2, 0] 0.139
 Paracardial AT  (cm2) − 1 ± 3 0 ± 3 − 1 [− 3, 1] 0.467
 Hepatic TGC (%) − 1.9 ± 3.6 − 3.2 ± 5.5 − 0.3 [− 2.6, 2.0] 0.807
 Myocardial TGC (%) 0.1 ± 0.5 − 0.1 ± 0.6 0.2 [− 0.1, 0.5] 0.157
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However, in contrast to the intention-to-treat analysis, in 
the per-protocol analysis, treatment with liraglutide sig-
nificantly reduced HbA1c compared to placebo. Interest-
ingly, a previously published meta-analysis showed that 
the HbA1c-lowering effect of GLP-1 analogues is greater 
in studies with ≥ 50% Asian participants than in stud-
ies with < 50% Asians [39]. Therefore, possibly, in South 
Asian patients with type 2 diabetes treatment with lira-
glutide exerts more substantial or diverse effects, result-
ing in a greater reduction of HbA1c. An explanation for 
this observation could be differences in either insulin 
sensitivity or beta-cell function between South Asians 
and other ethnic groups. Importantly, since the change 
in visceral adipose tissue and the change in HbA1c show 
a strong association, it is likely that the reduction of vis-
ceral adipose tissue contributed to the improved glycae-
mic control.
Based on our data and current literature, we can 
speculate on the mechanism behind the liraglutide-
induced reduction of visceral adipose tissue in our 
per-protocol analysis. It has previously been shown 
that GLP-1 increases the expression of lipolytic mark-
ers while reducing expression of lipogenic and adi-
pogenic genes in adipose tissue, with distinct effects 
on subcutaneous and visceral adipose tissue [40]. In 
another study, expression of brown adipose tissue-
related genes was upregulated in subcutaneous adi-
pose tissue of rats after treatment with liraglutide [41]. 
In line, it was recently shown that liraglutide-induced 
weight reduction resulted in a greater reduction of vis-
ceral adipose tissue volume than lifestyle counselling at 
similar weight reduction [42]. Another possible expla-
nation for a specific reduction in visceral adipose tissue 
may be related to central effects of GLP-1. In rodents, 
activation of central GLP-1 receptors contributes sub-
stantially to improved insulin sensitivity [43] as related 
to an increase in sympathetic outflow [44]. Sympathetic 
innervation of visceral and subcutaneous adipose tissue, 
the principal initiator for lipolysis in white adipose tis-
sue, is partially separated [45]. Therefore, central action 
of GLP-1 analogues might induce specific lipolysis in 
visceral adipose tissue as compared to subcutaneous 
adipose tissue.
It has previously been proposed that the subcutaneous 
adipose tissue compartment is less developed in South 
Asians compared to white people, resulting in a reduced 
storage capacity of this compartment causing more stor-
age of fat in ectopic sites [46]. Furthermore, South Asians 
have an increased subcutaneous adipose tissue adipocyte 
size compared to white Caucasians, probably related to 
limited expansion of this depot, further contributing to 
overflow of fatty acids to ectopic depots [11]. Our results 
implicate that GLP-1 analogues could be an effective 
treatment option for South Asian patients with type 2 
diabetes, possibly through improving insulin sensitiv-
ity via a specific reduction in visceral adipose tissue. If 
reduction in visceral adipose tissue is indeed causal for 
the improvement of HbA1c, GLP-1 analogues are likely 
to be also beneficial for other patients with high amounts 
of ectopic fat. All in all, it is clear that liraglutide and 
other GLP-1 analogues decrease body weight related 
to a specific decrease in visceral adipose tissue. Further 
research is warranted to determine treatment effects in 
different ethnic groups and in subjects with different 
body compositions.
The main strength of this study is the randomised, dou-
ble-blind, placebo-controlled trial design. In addition, the 
study design in which participants were treated accord-
ing to current clinical guidelines increases the external 
validity of our results. Moreover, we had no drop-out and 
study drug compliance was generally high. Furthermore, 
we performed a per-protocol analysis excluding partici-
pants with a low drug adherence or missing data on drug 
adherence. Limitations are that our study was powered 
Fig. 2 The effect of liraglutide and placebo on different adipose 
tissue compartments. Percentual changes are depicted after 
26 weeks of treatment with liraglutide (n = 24) and placebo (n = 20) 
compared to baseline. Box and whiskers show 25th and 75th 
percentile and 10th and 90th percentile, respectively. Missing data in 
liraglutide‑group: n = 3 for epicardial AT and paracardial AT. Missing 
data in placebo‑group: n = 3 for epicardial AT, n = 2 for paracardial 
AT and n = 1 for Myocardial TGC. AT adipose tissue, TGC triglyceride 
content. *P < 0.05
Page 10 of 12van Eyk et al. Cardiovasc Diabetol           (2019) 18:87 
on other outcome measures than the outcomes reported 
here, and the relatively small group size.
Conclusions
In summary, in this randomised, placebo-controlled 
trial, we showed that liraglutide decreases body weight, 
which is partially caused by a reduction of visceral adi-
pose tissue, and improves HbA1c in South Asian type 2 
diabetes patients. Interestingly, the reduction of visceral 
adipose tissue was associated with a reduction in HbA1c. 
Collectively, these data indicate that GLP-1 analogues 
might be useful therapeutic means to improve glycae-
mic control by reducing visceral adipose tissue volume in 
South Asian type 2 diabetes patients.
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